<DOC>
	<DOCNO>NCT00223964</DOCNO>
	<brief_summary>This multi-center study iron-deficient pediatric hemodialysis patient , whose legal guardian provide sign informed consent satisfy inclusion exclusion criterion .</brief_summary>
	<brief_title>Study Efficacy Two Doses Ferrlecit Treatment Iron Deficiency Pediatric Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female pediatric endstage renal disease ( ESRD ) patient . Predetermined TSAT serum ferritin level Receiving chronic hemodialysis therapy identify need repletion iron therapy . Receiving stable epoetin ( EPO ) dose regimen . Receipt form iron supplement 4 week prior first Ferrlecit® dose . Blood transfusion . Hypersensitivity Ferrlecit® . Significant inflammatory condition .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Iron Deficiency</keyword>
	<keyword>Anemia Pediatric Hemodialysis</keyword>
</DOC>